

040804

14023 U.S. PTO

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new non-provisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No.	AFD 490A
First Inventor or Application Identifier	Harvey A. Schwertner
Title	BILIRUBIN TESTS AS RISK PREDICTORS FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND PSORIATIC ARTHRITIS
Express Mail Label No.	EE380648293US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

ADDRESS TO: MS Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

1. *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)

2. Applicant claims small entity status
(See 37 CFR 1.27)

3. Specification [Total Pages 48]
(Preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure

4. Drawing(s) (35 U.S.C. 113) [Total Sheets 9]

5. Oath or Declaration [Total Pages 1]
 a. Newly executed (original or copy)
 b. Copy from a prior application (37 CFR 1.63(d))
 (for continuation/divisional with Box 18 completed)
 i. **DELETION OF INVENTOR(S)**
 Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

6. Application Data Sheet. See 37 CFR 1.76

7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)

8. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

a. Computer Readable Form (CRF)

b. Specification Sequence Listing on:
 i. CD-ROM or CD-R (2 copies); or
 ii. Paper

c. Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. Assignment Papers (cover sheet & document(s))

10. 37 CFR 3.73(b) Statement Power of Attorney

11. English Translation Document (if applicable)

12. Information Disclosure Statement (IDS) PTO/SB/08A Copies of IDS Citations

13. Preliminary Amendment

14. Return Receipt Postcard (MPEP 503) (should be itemized)

15. Certified Copy of Priority Document(s)

16. Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach for PTO/SB/35 or its equivalent.

17. Other: _____

18. If a **CONTINUING APPLICATION**, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76

Continuation Divisional Continuation in Part (CIP) of prior application No: 10/016,826

Prior application information: Examiner M. Wallenhorst Group / Art Unit 1743

For **CONTINUATION or DIVISIONAL APPS** only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5B, is considered to be a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

CORRESPONDENCE ADDRESS

<input checked="" type="checkbox"/> Customer Number		26902 (Insert Customer No. here)		or <input type="checkbox"/> Correspondence address below	
Name	FREDRIC L. SINDER				
Address	AFMCLO/JAZ BLDG 11, ROOM 100 2240 B STREET				
City	WRIGHT-PATTERSON AFB		State	OH	Zip Code
Country	U.S.A.		Telephone	(937) 255-2838	Fax (937) 255-3733

Name (Print / Type)	FREDRIC L. SINDER	Registration No. (Attorney / Agent)	28,475
Signature	<i>Fredric L. Sinder</i>	Date	7 Apr. 1 2004

17548 U.S.P.T.O.
10/828526

040804

FEE TRANSMITTAL

for FY 2004

Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 856.00)

METHOD OF PAYMENT

Check Credit Card Money Order Other Order None

Deposit Account Number

AF 01-0465

Deposit Account Name

Department of the Air Force

The Commissioner is authorized to: (check all that apply)

Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) during the pendency of this application
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee	Small Entity Fee	Fee Description	Fee Paid
Code (\$)	Code (\$)		
1001 770	2001 385	Utility Filing Fee	770
1002 340	2002 170	Design Filing Fee	
1003 530	2003 265	Plant Filing Fee	
1004 770	2004 385	Reissue Filing Fee	
1005 160	2005 80	Provisional Filing Fee	

SUBTOTAL (1) \$ 770.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
4	- 20** =	0	0
4	- 3** =	1	86
Multiple Dependent			

Large Entity Fee Code	Small Entity Fee Code	Fee Description
1202 18	2202 9	Claims in excess of 20
1201 86	2201 43	Independent claims in excess of 3
1203 290	2203 145	Multiple dependent claim, if not paid
1204 86	2204 43	**Reissue independent claims over original patent
1205 18	2205 9	**Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) \$ 86.00

**or number previously paid, if greater; For Reissues, see above

Complete if Known

Application Number

Filing Date

First Named Inventor Harvey A. Schwertner

Examiner Name

Group Art Unit

Attorney Docket Number AFD 490A

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Code	Small Entity Code	Fee Description	Fee Paid
1051	2051	Surcharge - late filing fee or oath	
1052	2052	Surcharge - late provisional filing fee or cover sheet	
1053	1053	Non-English specification	
1812	1812	For filing a request for <i>ex parte</i> reexamination	
1804	1804	Requesting publication of SIR prior to Examiner Action	
1805	1805	Requesting publication of SIR after Examiner action	
1251	2251	Extension for reply within first month	
1252	2252	Extension for reply within second month	
1253	2253	Extension for reply within third month	
1254	2254	Extension for reply within fourth month	
1255	2255	Extension for reply within fifth month	
1401	2401	Notice of Appeal	
1402	2402	Filing a brief in support of an appeal	
1403	2403	Request for oral hearing	
1451	1451	Petition to institute a public use proceeding	
1452	2452	Petition to revive - unavoidable	
1453	2453	Petition to revive - unintentional	
1501	2501	Utility issue fee (or reissue)	
1502	2502	Design issue fee	
1503	2503	Plant issue fee	
1460	1460	Petitions to the Commissioner	
1807	1807	Processing fee under 37 CFR 1.17(q)	
1806	1806	Submission of Information Disclosure Stmt	
8021	8021	Recording each patent assignment per property (times number of properties)	
1809	2809	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	2810	For each additional invention to be examined (37 CFR 1.129(b))	
1801	2801	Request for Continued Examination (RCE)	
1802	1802	Request for expedited examination of a design application	


Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) \$ 0

SUBMITTED BY

Complete (if applicable)

Typed or Printed Name	FREDERIC L. SINDER	Registration. No.	28,475	Telephone	(937) 255-2838
Signature				Date	7 April 2004
Typed or Printed Name		Registration. No.		Telephone	
Signature				Date	

**REQUEST AND CERTIFICATION
UNDER
35 U.S.C. 122(b)(2)(B)(i)**

First Named Inventor	Harvey A. Schwertner
Title	BILIRUBIN TESTS AS RISK PREDICTORS FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND PSORIATIC ARTHRITIS
Atty Docket Number	AFD 490A

I hereby certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 1.22(b).

1 April 2004

Date



Signature

FREDRIC L. SINDER

Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and be submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).**